RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. The company is headquartered in Rockville, Maryland and currently employs 2 full-time employees. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The firm's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The firm's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Industry: Pharmaceutical Preparations Peers: Serina Therapeutics Inc Sio Gene Therapies Inc. Bio Path Holdings Inc Onconetix Inc Cellectar Biosciences Inc Forte Biosciences Inc Inhibikase Therapeutics Inc Vincerx Pharma, Inc. Oncorus, Inc.